"The 30-day postoperative rate of Clostridium difficile infection (CDI) was significantly associated with the number of antibiotic classes given in the 60 days before surgery and the complexity of the surgery, according to a study of almost"...
The following serious adverse reactions are described in greater detail in the WARNINGS AND PRECAUTIONS section
- Hypersensitivity Reactions [see WARNINGS AND PRECAUTIONS]
- Clostridium difficile-Associated diarrhea [see WARNINGS AND PRECAUTIONS]
- Direct Coombs' Test Seroconversion [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be compared directly to rates from clinical trials of another drug and may not reflect rates observed in practice.
Teflaro was evaluated in four controlled comparative Phase 3 clinical trials (two in ABSSSI and two in CABP) which included 1300 adult patients treated with Teflaro (600 mg administered by IV over 1 hour every 12h) and 1297 patients treated with comparator (vancomycin plus aztreonam or ceftriaxone) for a treatment period up to 21 days. The median age of patients treated with Teflaro was 54 years, ranging between 18 and 99 years old. Patients treated with Teflaro were predominantly male (63%) and Caucasian (82%).
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
In the four pooled Phase 3 clinical trials, serious adverse reactions (SARs) occurred in 98/1300 (7.5%) of patients receiving Teflaro and 100/1297 (7.7%) of patients receiving comparator drugs. Treatment discontinuation due to adverse reactions occurred in 35/1300 (2.7%) of patients receiving Teflaro and 48/1297 (3.7%) of patients receiving comparator drugs with the most common adverse reactions leading to discontinuation being hypersensitivity for both treatment groups at a rate of 0.3% in the Teflaro group and 0.5% in comparator group.
Most Common Adverse Reactions
No adverse reactions occurred in greater than 5% of patients receiving Teflaro. The most common adverse reactions occurring in > 2% of patients receiving Teflaro in the pooled phase 3 clinical trials were diarrhea, nausea, and rash.
Table 4 lists adverse reactions occurring in ≥ 2% of patients receiving Teflaro in the pooled Phase 3 clinical trials.
Table 4: Adverse Reactions Occurring in ≥ 2% of
Patients Receiving Teflaro in the Pooled Phase 3 Clinical Trials
|Adverse Reactions||Pooled Phase 3 Clinical Trials (four trials, two in ABSSSI and two in CABP)|
|Diarrhea||5 %||3 %|
|Nausea||4 %||4 %|
|Constipation||2 %||2 %|
|Vomiting||2 %||2 %|
|Increased transaminases||2%||3 %|
|Metabolism and Nutrition disorders|
|Hypokalemia||2 %||3 %|
|Skin and Subcutaneous Tissue Disorders|
|a Comparators included vancomycin 1 gram IV every 12h plus aztreonam 1 gram IV every 12h in the Phase 3 ABSSSI trials, and ceftriaxone 1 gram IV every 24h in the Phase 3 CABP trials.|
Other Adverse Reactions Observed During Clinical Trials of Teflaro
Following is a list of additional adverse reactions reported by the 1740 patients who received Teflaro in any clinical trial with incidences less than 2%.
Gastrointestinal disorders -Abdominal pain
General disorders and administration site conditions -Pyrexia
Hepatobiliary disorders -Hepatitis
Immune system disorders -Hypersensitivity, Anaphylaxis
Infections and infestations -Clostridium difficile colitis
Nervous system disorders -Dizziness, Convulsion
Renal and urinary disorders -Renal failure
Skin and subcutaneous tissue disorders -Urticaria
The following adverse reaction has been identified during postapproval use of Teflaro. Because this adverse reaction was reported voluntarily from a population of uncertain size, it is not possible to estimate its frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: Agranulocytosis.
Read the Teflaro (ceftaroline fosamil injection for intravenous (iv) use) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 9/15/2015
Additional Teflaro Information
Taxotere - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.